Anthem Biosciences Limited Reports Q1 FY27 Net Profit of ₹1,199 Million on Revenues of ₹4,182 Million

Anthem Biosciences Limited published its unaudited consolidated financial results for the first quarter ended June 30, 2026 (Q1 FY27).

The innovation-driven Contract Research, Development, and Manufacturing Organization (CRDMO) and Specialty Ingredients manufacturer reported a consolidated Net Profit After Tax (PAT) of ₹1,199.41 million for the quarter, supported by stable operational gross margins across its core segments.

Consolidated Financial Performance Overview

(All monetary figures in ₹ Million, unless otherwise specified)

Revenue from Operations: Stood at ₹4,182.18 million for Q1 FY27, compared to ₹5,402.09 million in the corresponding quarter of the previous fiscal year (Q1 FY26) and ₹6,109.43 million in the preceding quarter (Q4 FY26).

Other Income: Reached ₹248.88 million during the quarter (vs. ₹228.12 million in Q1 FY26).

Total Income: Stood at ₹4,431.07 million, compared to ₹5,630.21 million in Q1 FY26.

Profit Before Tax (PBT): Reported at ₹1,445.81 million for Q1 FY27, compared to ₹1,862.48 million in Q1 FY26 and ₹2,779.16 million in Q4 FY26.

Net Profit After Tax (PAT): Reached ₹1,199.41 million, compared to ₹1,357.91 million in Q1 FY26 and ₹1,897.58 million in Q4 FY26.

Total Comprehensive Income: Stood at ₹1,208.61 million (inclusive of ₹9.20 million in other comprehensive income), compared to ₹1,373.18 million in Q1 FY26.

Segmental Revenue & Gross Profit Breakdown

1. Contract Research, Development, and Manufacturing Organization (CRDMO)

Segment Revenue: Accounted for ₹3,408.02 million (representing 81.5% of operational revenue), compared to ₹4,527.11 million in Q1 FY26.

Segment Gross Profit: Reached ₹2,322.57 million (delivering a segment gross margin of 68.1%), compared to ₹2,648.72 million in Q1 FY26.

2. Specialty Ingredients

Segment Revenue: Generated ₹774.16 million (representing 18.5% of operational revenue), compared to ₹874.98 million in Q1 FY26.

Segment Gross Profit: Reached ₹397.62 million (delivering a segment gross margin of 51.4%), compared to ₹444.60 million in Q1 FY26.

Consolidated Expense Summary

Total expenses for Q1 FY27 dropped to ₹2,985.25 million, down from ₹3,767.73 million in Q1 FY26 and ₹3,852.19 million in Q4 FY26:

Cost of Materials Consumed: ₹1,485.63 million (down from ₹1,622.05 million in Q1 FY26).

Changes in Inventories: Reported at ₹(23.64) million.

Employee Benefit Expenses: Stood at ₹788.36 million (vs. ₹720.32 million in Q1 FY26).

Other Expenses: Accounted for ₹426.16 million (vs. ₹458.08 million in Q1 FY26).

Depreciation & Amortization Expense: Stood at ₹299.87 million (vs. ₹264.46 million in Q1 FY26).

Finance Cost: Remained low at ₹8.87 million.

Tax Provisioning: Total tax outlay was ₹246.40 million, benefiting from a deferred tax credit of ₹100.65 million against current tax of ₹347.05 million.

Share Capital & Earnings Per Share (EPS)

Paid-Up Equity Share Capital: Expanded to ₹1,126.77 million (Face value of ₹2/- per share).

Other Equity: Stood at ₹29,301.73 million as per the audited balance sheet for the year ended March 31, 2026.

Basic Earnings Per Share: Reported at ₹2.13 per share for the quarter (not annualized), compared to ₹2.43 in Q1 FY26 and ₹3.38 in Q4 FY26.

Diluted Earnings Per Share: Reported at ₹2.11 per share for Q1 FY27.

Source : Equity Bulls

Keywords

AnthemBiosciences Q1FY27 Q1FY2027 ResultUpdate